Entering text into the input field will update the search result below

BiondVax universal flu vaccine candidate successful in mid-stage study; shares ahead 9% premarket

Jul. 20, 2017 9:06 AM ETScinai Immunotherapeutics Ltd. (SCNI) StockBy: Douglas W. House, SA News Editor
  • Thinly traded nano cap BiondVax Pharmaceuticals (NASDAQ:BVXV) is up 9% premarket on increased volume in response to its announcement of positive results from a Phase 2b clinical trial assessing universal flu vaccine candidate M-001. The study met both endpoints of safety and influenza-specific cellular immune responses.
  • The company intends to advance M-001 into Phase 3 development.

Recommended For You

More Trending News

About SCNI Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SCNI--
Scinai Immunotherapeutics Ltd.